XML 43 R36.htm IDEA: XBRL DOCUMENT v3.21.4
Note 3 - Collaboration Revenue (Details Textual)
$ / shares in Units, ¥ in Thousands, $ in Thousands
 1 Months Ended 3 Months Ended 9 Months Ended 31 Months Ended
Nov. 12, 2020
$ / shares
shares
Nov. 30, 2020
USD ($)
Sep. 30, 2021
USD ($)
Sep. 30, 2020
USD ($)
Sep. 30, 2021
USD ($)
Sep. 30, 2020
USD ($)
Nov. 12, 2022
$ / shares
shares
Sep. 30, 2021
CNY (¥)
Revenue from Contract with Customer, Including Assessed Tax     $ 337 $ 0 $ 1,013 $ 0    
Dalian Wanchunbulin Pharmaceuticals Ltd. (“Wanchunbulin”) [Member] | Jiangsu Hengrui Pharmaceuticals Co., Ltd. [Member]                
Collaboration Agreement, Upfront Cash Payment     31,039   31,039     ¥ 200,000
Research Collaboration and License Agreement with Eli Lilly [Member] | Series A-2 Preferred Shares [Member]                
Redeemable Noncontrolling Interest, Equity, Preferred, Fair Value     5,267   5,267      
Research Collaboration and License Agreement with Eli Lilly [Member] | SEED Therapeutics Inc. [Member]                
Collaborative Arrangement, Upfront Cash Payment   $ 10,000            
Derivative Liability, Total     278   278      
Revenue from Contract with Customer, Including Assessed Tax     337   1,013      
Collaboration Agreement,, Maximum Regulatory Development Milestones to be Received     108,638   108,638     700,000
Collaboration Agreement, Maximum Commercial Milestones to be Received     62,079   62,079     ¥ 400,000
Revenue from Contract with Customer, Excluding Assessed Tax, Total     $ 0   $ 0      
Research Collaboration and License Agreement with Eli Lilly [Member] | SEED Therapeutics Inc. [Member] | Series A-1 Convertible Preferred Shares [Member]                
Stock Issued for Transfer of Assets, Shares (in shares) | shares 9,631,941              
Research Collaboration and License Agreement with Eli Lilly [Member] | SEED Therapeutics Inc. [Member] | Series A-1 Preferred Shares [Member]                
Stock Issued During Period, Shares, New Issues (in shares) | shares 1,194,030              
Research Collaboration and License Agreement with Eli Lilly [Member] | SEED Therapeutics Inc. [Member] | Series A-2 Preferred Shares [Member]                
Stock Issued During Period, Shares, New Issues (in shares) | shares 1,990,000              
Shares Issued, Price Per Share (in dollars per share) | $ / shares $ 2.5125              
Research Collaboration and License Agreement with Eli Lilly [Member] | SEED Therapeutics Inc. [Member] | Additional Series A-2 Preferred Shares [Member] | Forecast [Member]                
Stock Issued During Period, Shares, New Issues (in shares) | shares             1,990,000  
Shares Issued, Price Per Share (in dollars per share) | $ / shares             $ 2.5125  
Research Collaboration and License Agreement with Eli Lilly [Member] | SEED Therapeutics Inc. [Member] | Maximum [Member]                
Collaborative Arrangement, Equity Investment   $ 780,000